The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis

Author(s):  
Tian-Run Lv ◽  
Hai-Jie Hu ◽  
Fei Liu ◽  
Parbatraj Regmi ◽  
Yan-Wen Jin ◽  
...  
Author(s):  
Gun Ha Kim ◽  
Pyeong Hwa Kim ◽  
Jin Hyoung Kim ◽  
Pyo-Nyun Kim ◽  
Hyung Jin Won ◽  
...  

2019 ◽  
Vol 9 (6) ◽  
pp. 740-748 ◽  
Author(s):  
Ali Yousaf ◽  
Jin U. Kim ◽  
Joseph Eliahoo ◽  
Simon D. Taylor-Robinson ◽  
Shahid A. Khan

HPB ◽  
2019 ◽  
Vol 21 (7) ◽  
pp. 784-792 ◽  
Author(s):  
Rui Zhou ◽  
Dihan Lu ◽  
Wenda Li ◽  
Wenliang Tan ◽  
Sicong Zhu ◽  
...  

2017 ◽  
Vol 22 (4) ◽  
pp. 883-891 ◽  
Author(s):  
Ya-Qing Zhang ◽  
Fei Zhao ◽  
Lei Song ◽  
Hong-Yun Gan ◽  
Xiao-Feng Xie

Many studies have investigated the efficacy of Endostar combined with transcatheter arterial chemoembolization (TACE) versus TACE alone for hepatocellular carcinoma (HCC). A systematic review was conducted to evaluate the efficacy of Endostar. PubMed, Embase, and other databases were searched, and meta-analysis was performed using RevMan 5.3 software. Nine studies, all of which were clinical randomized controlled trials, involving 411 participants were included. The overall response rate, disease control rate and α-fetoprotein negative conversion ratio, and the 6- and 12-month survival rate of HCC patients treated with combined Endostar and TACE were higher than those treated with TACE alone ( P < .01). Furthermore, the incidence of tumor progression was low after Endostar treatment ( P = .005). The incidence of adverse effects (leukocytopenia, liver function damage, and vomiting) was similar in Endostar with TACE and in TACE alone ( P > .05). However, large studies and more randomized trials are necessary to determine the effects of Endostar on HCC.


Sign in / Sign up

Export Citation Format

Share Document